Abstract

Abstract Pharmacogenomic testing has emerged as a promising tool in personalized medicine, allowing healthcare professionals to tailor therapies based on individual genetic profiles. This article explores the transformative impact of pharmacogenomics through case studies in oncology and psychiatry. In oncology, pharmacogenomic testing has optimized treatment strategies for breast and colorectal cancer by identifying genetic variations that influence drug metabolism and response. Similarly, in psychiatry, pharmacogenomics has revolutionized antidepressant and antipsychotic therapy by guiding medication selection and dosage adjustment based on genetic factors. Despite challenges in adoption and implementation, ongoing research efforts are enhancing the utility of pharmacogenomic testing in clinical practice, offering the potential for improved treatment outcomes and reduced adverse reactions.